Last reviewed · How we verify

Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes — Portfolio Competitive Intelligence Brief

Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
medical nutrition therapy + metformin medical nutrition therapy + metformin marketed Combination therapy: dietary intervention + biguanide antidiabetic AMP-activated protein kinase (AMPK) and hepatic glucose metabolism (metformin component) Endocrinology / Diabetes
Orally Colostrum Orally Colostrum phase 3 Biological supplement / Immunomodulator Immunology / Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes:

Cite this brief

Drug Landscape (2026). Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-nacional-de-perinatologia-isidro-espinosa-de-los-reyes. Accessed 2026-05-17.

Related